Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Leqembi Approved in UK: Eisai
August 23, 2024
- Bayer Japan Says No Job Cuts to Soothe Employees’ Nerves as Xarelto Generics Loom
August 23, 2024
- Lilly’s BTK Inhibitor Jaypirca Hits Japan Market for MCL
August 22, 2024
- A Time for Patience - 1: New Drugs for ALS Emerging, Some Close to Approval; Can They Meet Unmet Needs?
August 22, 2024
- Rakuten Medical Japan VP Kodama Promoted to President
August 22, 2024
- Keytruda Regains Top-Selling Status in Japan in April-June: IQVIA
August 21, 2024
- Padcev Approved for Bladder Cancer in China: Astellas
August 21, 2024
- GSK’s Consumer Unit in Japan to Rebrand as Haleon in September
August 20, 2024
- Bayer Set to Finally List Xarelto AG in December, Espha as Distributor
August 20, 2024
- Enhertu Bags Breakthrough Therapy Tag for HER2 Low or Ultralow Breast Cancer
August 20, 2024
- Enhertu Grabs Conditional Nod for Gastric Cancer in China: Daiichi Sankyo
August 20, 2024
- Cheplapharm Snags 2 More Brands from Clinigen in Japan
August 20, 2024
- Otsuka Rolls Out Therapeutic App for Depression in US
August 19, 2024
- Fabhalta, Omjjara, Avigan Now Available in Japan
August 19, 2024
- Takeda Gets Japan Approval for Low-Dose Form of Ninlaro
August 19, 2024
- Insud/ASKA’s Birth Control Pill Approved in South Korea
August 19, 2024
- Breyanzi Broadens Label for Follicular Lymphoma in Japan: BMS
August 19, 2024
- Chugai Files DMD Gene Therapy Elevidys in Japan
August 19, 2024
- Rinvoq Filed for Giant Cell Arteritis in Japan: AbbVie
August 19, 2024
- Eisai’s Leqembi Now Approved in UAE
August 19, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…